Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.60 |
| ▸ | RORA | P35398 | 1/20 | 0.60 |
| ▸ | RORB | Q92753 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30660958 | 1.00 | RORC (0.67) | RORCNR1I2RORARORB | |
| SCHEMBL22278613 | 0.86 | RORC (0.75) | RORCNR1I2RORARORB | |
| SCHEMBL30660968 | 0.86 | RORC (0.75) | RORCNR1I2RORARORB | |
| SCHEMBL22278651 | 0.84 | RORC (0.62) | RORCNR1I2RORARORB | |
| SCHEMBL30816102 | 0.84 | RORC (0.62) | RORCNR1I2RORARORB | |
| SCHEMBL23102394 | 0.84 | RORC (0.62) | RORCNR1I2RORARORB | |
| SCHEMBL22278662 | 0.83 | RORC (0.58) | RORCNR1I2RORARORB | |
| SCHEMBL24061203 | 0.83 | RORC (0.66) | RORCNR1I2RORARORB | |
| SCHEMBL24061260 | 0.82 | RORC (0.70) | RORCNR1I2RORARORB | |
| SCHEMBL22278761 | 0.82 | RORC (0.67) | RORCNR1I2RORARORB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112839931-B | 1,2,3, 4-tetrahydroquinoxaline derivative, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20220009894-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2022-01-13 | — | — | US | disclosed |
| EP-3915977-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2021-12-01 | — | — | EP | disclosed |
| CN-112839931-A | 1,2,3, 4-tetrahydroquinoxaline derivative and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2021-05-25 | — | — | CN | disclosed |
| WO-2020151232-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009894-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RORA, RORB, RORC | RORC 3/4885NR1I2 39/4885RORA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.